Hepatitis B DNA vaccine - GENimmune

Drug Profile

Hepatitis B DNA vaccine - GENimmune

Alternative Names: EP 2210; EP-HBS; GCR 3697; GNI-102; HBV DNA vaccine - Pharmexa-Epimmune/Innogenetics; HBV polyepitope vaccine - GENimmune; Hepatitis B Virus polyepitope vaccine candidate - GENimmune; INNO 102; INX-102-3697

Latest Information Update: 14 Oct 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genencor International; Pharmexa-Epimmune
  • Developer GENimmune
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 12 Feb 2008 Discontinued - Phase-I for Hepatitis B in USA (IM)
  • 12 Feb 2008 GNI 102 is available for licensing (http://www.genimmune-nv.com)
  • 27 Nov 2007 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top